6.10
6.10 (0%)
As of Apr 28, 2025
Vir Biotechnology, Inc. [VIR]
Source:
Company Overview
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | 415-906-4324 |
| Industry | manufacturing |
| CEO | Marianne De Backer |
| Website | www.vir.bio |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $74.2 |
| Operating Profit | $-587.2 |
| Net Income | $-522 |
| Net Cash | $57.4 |
Profit Ratios
| Gross Margin | $73.4 |
| Operating Margin | -791.3 |
| Profit as % of Revenues | -14.1% |
| Profit as % of Assets | -31.5% |
| Profit as % of Stockholder Equity | -45.4% |
Management Effectiveness
| Return on Equity | -45.4% |
| Return on Assets | -37.3% |
| Turnover Ratio | 4.5% |
| EBITA | $-587.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,398.8 |
| Total Liabilities | $248.4 |
| Operating Cash Flow | $-446.4 |
| Investing Cash Flow | $499.4 |
| Financing Cash Flow | $4.4 |
